neurocare key facts
- Developer of a digital therapy platform (DTP) designed to empower clinicians to deliver best practices.
- neurocare’s last known valuation is $75.8M (Jan 2024).
- It has raised $20.0M; the latest was PE Growth/Expansion ($20.0M) in Feb 2025.
- Notable investors include Plutus Investment Group, Additio Investment Group, Aescuvest, Convergence Partners (Switzerland), Impact Expansion — 13 tracked in total.
- Status: Acquired/Merged.
Who backs neurocare
13+- ·The complete investor list: 13 names
- ·Watch neurocare: the Monday email on marks, rounds and moves
neurocare funding rounds
No funding rounds for neurocare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
neurocare valuation
neurocare's last known valuation is $75.8 million, from Jan 2024. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
neurocare investors
13 investors are on record for neurocare, including Plutus Investment Group, Additio Investment Group, Aescuvest and Convergence Partners (Switzerland).
About neurocare
Developer of a digital therapy platform (DTP) designed to empower clinicians to deliver best practices. The company's platform offers fully personalized practice features, factoring in brain activity, sleep, biomarkers and other lifestyle factors and metrics to deliver a completely tailored and individualized program, enabling patients to get a measurable and effective clinical approach that is based on the natural ability to learn about neuroplasticity conveniently.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2014
- Employees
- 200
- Website
- neurocaregroup.com/
- Ownership
- Acquired/Merged
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
neurocare’s last known valuation, Jan 2024. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.